Shots:
AstraZeneca has entered a worldwide exclusive research collaboration & licensing agreement with insitro to discover novel targets and advance therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies using AI
As per the deal, insitro will receive $40M upfront and is eligible for up to ~$1.46B in discovery, development & commercial milestones, plus single-digit royalties…
